Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients
This study is not yet open for participant recruitment.
Verified November 2011 by Cardiff and Vale University Health Board
Sponsor:
Cardiff and Vale University Health Board
Collaborator:
Cardiff University
Information provided by (Responsible Party):
Matt P Wise, Cardiff and Vale University Health Board
ClinicalTrials.gov Identifier:
NCT01482988
First received: November 29, 2011
Last updated: November 30, 2011
Last verified: November 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The principal aim of this study is to establish if a polymorphism in a gene important for innate immunity to fungi represents a significant risk factor for the development of Candida colonisation and subsequent invasive candidosis in critically ill patients. Incorporation of a screening programme onto a risk-based algorithm for critical care patients would allow more effective targeting of molecular diagnostic tests, anti-fungal prophylaxis and targeted treatment. Sequential critical care patients will be screened for gene polymorphisms and undergo regular screening for Candida colonization.
| Condition |
|---|
|
Critically Ill |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients |
Resource links provided by NLM:
Further study details as provided by Cardiff and Vale University Health Board:
| Estimated Enrollment: | 600 |
| Study Start Date: | December 2011 |
| Groups/Cohorts |
|---|
| Critical care patients antipated to stay more than 72 hours |
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Critical care patients predicted to stay more than 72 hours
Criteria
Inclusion Criteria:
- Patients aged > 18 years
- Patients with anticipated or actual critical care unit stay > 72 hours
- Consent or assent (if patient lacks capacity) obtained
Exclusion Criteria:
- Age < 18 years
- Length of predicted stay on critical care < 72 hours consent or assent not obtained
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01482988
Contacts
| Contact: Matt P Wise | +44 2920 747747 ext 3608 | mattwise@doctors.org.uk |
| Contact: Nicki Haskins | +44 2920 747747 ext 3608 | nicki.haskins@wales.nhs.uk |
Locations
| United Kingdom | |
| Critical Care Unit | Not yet recruiting |
| University Hospital of Wales, Cardiff, United Kingdom, CF14 4XW | |
| Contact: Matt P Wise +44 2920 747747 ext 3608 mattwise@doctors.org.uk | |
| Sub-Investigator: Matt P Wise | |
Sponsors and Collaborators
Cardiff and Vale University Health Board
Cardiff University
Investigators
| Principal Investigator: | Rosemary Barnes | Cardiff University |
| Principal Investigator: | Matt P Wise | Cardiff and Vale Local Health Board |
More Information
No publications provided
| Responsible Party: | Matt P Wise, Critical Care Consultant, Cardiff and Vale University Health Board |
| ClinicalTrials.gov Identifier: | NCT01482988 History of Changes |
| Other Study ID Numbers: | 11/WA/0340 |
| Study First Received: | November 29, 2011 |
| Last Updated: | November 30, 2011 |
| Health Authority: | Wales:Cardiff University Wales:Cardiff and Vale University Health Board |
Keywords provided by Cardiff and Vale University Health Board:
|
prevalence of the Dectin-1 polymorphism (Tyr238X) |
Additional relevant MeSH terms:
|
Critical Illness Disease Attributes Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013